Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Improving Oral Peptide Delivery Through Structural Modifications – CSO, Dr Jan Jezek in PharmaTech article

2 November 2026

Investor presentation – October 2026

26 October 2026

Arecor expands international IP protection for concentrated ultra-rapid acting insulins enabling next generation of AID systems

15 October 2026

Contact: ir@arecor.com